Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nanochip 400 510(k)

This article was originally published in The Gray Sheet

Executive Summary

Nanogen files a 510(k) for its Cystic Fibrosis Kit and Nanochip 400 microarray system for carrier testing in adults, as an aid to newborn screening and in confirmatory diagnostic testing in newborns and children. The genetic assay uses an automated multiplexing platform that tests for 23 mutations, which account for 90% of U.S. cystic fibrosis cases. In August 2005, the firm received one of several letters from FDA to in vitro diagnostic test makers warning that its tests were "integrated" diagnostic devices that require 510(k) clearance (1"The Gray Sheet" Aug. 22, 2005, p. 9)...

You may also be interested in...

Nanogen Moves Ahead With New Microarray System After FDA Warning

A warning letter issued to San Diego-based Nanogen Aug. 11 highlights the continued focus of the agency's in vitro diagnostic regulators on analyte-specific reagents (ASRs)

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts